Preclinical studies have shown that LDRT can reprogram the tumor immune microenvironment by transiently inflaming tumors, inducing macrophage M1 polarization, improving the tumor antigen presentation ability of DCs, and upregulating the expression of MHC class I and PD-L1 in tumor cells (27, 28). This evidence concerns the gene CD274 and neoplasm.